

Texas Vaccine Providers Webinar Highlights – April 5, 2022

Review the highlights of the topics covered in the April 5th webinar below or view the [full recording](#) for detailed information.

COVID-19 Vaccine Updates

- **Please Reference Below for Terminology Regarding COVID-19 Vaccine Dosing**
 - Primary series: For most people, a 2-dose series of an mRNA COVID-19 vaccine (Pfizer-BioNTech and Moderna) or a single dose of Janssen COVID-19 Vaccine. For people who are moderately or severely immunocompromised, a 3-dose series of an mRNA COVID-19 vaccine or a single dose of Janssen COVID-19 Vaccine.
 - Additional dose: A subsequent dose of vaccine administered to people who were less likely to mount a protective immune response after initial vaccination. People who are moderately or severely immunocompromised and who received Janssen COVID-19 Vaccine for their primary series should receive an additional dose.
 - Booster dose: A subsequent dose of vaccine administered to enhance or restore protection which might have waned over time after primary series vaccination.
 - Homologous booster dose: The same vaccine product used for the booster dose was administered for the primary series.
 - Heterologous booster dose (mix-and-match booster): The vaccine product used for the booster dose differs from the product administered for the primary series.
 - Up to date: A person has received all recommended doses in their primary vaccine series, and a booster dose, when eligible. **Receipt of a second booster dose is not necessary to be considered up to date at this time.**

COVID-19 Vaccine Clinical Reminders

- As per your provider agreement, organizations must provide an approved Emergency Use Authorization (EUA) fact sheet or vaccine information statement (VIS), to each vaccine recipient, the adult caregiver accompanying the recipient, or other legal representative before administering COVID-19 Vaccine. **Please refer to the [COVID-19 Vaccine EUA Recipient/Caregiver Fact Sheets | CDC](#) for additional details.**
- Recording dates and times ensure that the vaccine is actively monitored and stored according to the manufacturer’s guidelines for viability.

COVID-19 Vaccine Product Ordering Updates

- **Beginning May 2, 2022**, the Texas Department of State Health Services will be requiring all providers to report their current COVID-19 vaccine inventory by vaccine type in VAOS. In order to verify current COVID-19 vaccine inventory, DSHS will be sending out an inventory survey via email to collect doses of COVID-19 vaccine on hand, by vaccine type. **Providers should only report their current inventory on hand.** DO NOT include expired or wasted COVID-19 in the inventory survey.
 - Provider Group 1 survey due date on Friday, April 8 at 5:00 pm CST.
 - Provider Group 2 survey due date on Tuesday, April 12 at 5:00 pm CST.

Provider Resources:

- [COVID-19 Vaccine Management Resources \(training and support materials\)](#)
- [ImmTrac2 User Training Site](#)
- [ImmTrac2 Forms and Documents](#)
- [COVID-19 Vaccine Provider Enrollment Information](#)
- [CDC Clinical Considerations for or Use of mRNA COVID-19 Vaccines](#)
- [EUA Fact Sheet for Janssen Vaccine](#)
- DSHS Provider Help Desk: (833) 832-7068, 8 a.m. to 5 p.m., Monday through Friday; Email: COVID19VacEnroll@dshs.texas.gov

Live Q&A:

- Below are some of the questions DSHS subject matter experts answered during the webinar’s live Q&A sessions.**
- Will there be a further expiration extension for COVID-19 vaccines?
 - How many total doses of J&J can a person receive?
 - Are we required to report vaccine on VAOS if we have received it from a different source?
 - Once COVID-19 vaccines arrive, do we have to verify Quality Disposition Report before we administer or use them?
 - If an adult patient says they completed the COVID-19 series with an mRNA vaccine, including first booster, but then says they are immunocompromised, do they get a fourth dose or another booster?

